Related Experiment Videos
Cloning and characterization of the CDKN2A and p19ARF genes from Monodelphis domestica
T E Sherburn1, J M Gale, R D Ley
1Department of Cell Biology and Physiology, The University of New Mexico Health Science Center, Albuquerque 87131, USA.
Abstract:
The tumor suppressor gene, CDKN2A (p16), encodes a cyclin-dependent kinase inhibitor and functions as a negative regulator in the retinoblastoma pathway that blocks cell cycle progression from the G1 phase. The gene has been found to be deleted, truncated, mutated, or silenced by promoter methylation in a wide range of tumor types. Where melanoma CDKN2A mutations have been characterized, C --> T and CC --> TT transitions were found, indicating a direct role for ultraviolet radiation (UVR)-induced pyrimidine dimers in the formation of some tumors. The South American opossum, Monodelphis domestica, has been shown by our group and others to be susceptible to the induction of melanoma on chronic exposure to UVR alone. The CDKN2A gene and its exon 1beta alternate transcript p19ARF were cloned and sequenced from M. domestica to investigate the role of these genes in the development of UVR-induced melanoma and non-melanoma tumors. Both genes were first amplified by polymerase chain reaction (PCR) using cDNA from an opossum corneal-tumor cell-line library and degenerate primers based on human, mouse, and rat CDKN2A gene sequences. To verify these as normal sequences, both genes were then RT-PCR amplified from cultured normal opossum melanocyte mRNA. When comparing the tumor and melanocyte sequences, we found a UVR signature point mutation, a C --> T transition, within exon 2 in the corneal tumor cell line. The same mutation at this site in other tumors has been shown to alter the CDKN2A protein's ability to bind CDK4 kinase, which may lead to uncontrolled cell cycling. A comparison of the amino acid sequence of opossum CDKN2A showed identities relative to human, mouse, and rat between 57% and 63%, and when conserved amino acid substitutions are considered (similarity), the range is 63% to 67%. The amino acid identity and similarity for p19ARF ranged from 39% to 49%.
Insights
The CDKN2A gene, crucial for cell cycle regulation, was sequenced in South American opossums. A UVR-induced mutation was found in a corneal tumor, suggesting its role in melanoma development.
Area of Science:
- Genetics
- Molecular Biology
- Cancer Research
Background:
- The CDKN2A (p16) gene is a tumor suppressor regulating cell cycle progression.
- Mutations in CDKN2A are implicated in various cancers, including melanoma.
- Ultraviolet radiation (UVR) is a known factor in melanoma development, evidenced by specific mutation signatures.
Purpose of the Study:
- To investigate the role of the CDKN2A gene and its p19ARF transcript in UVR-induced melanoma and non-melanoma tumors in the South American opossum (Monodelphis domestica).
- To identify potential genetic alterations in CDKN2A associated with UVR exposure in this model organism.
Main Methods:
- Cloning and sequencing of the CDKN2A gene and p19ARF transcript from Monodelphis domestica.
- Amplification using polymerase chain reaction (PCR) and reverse transcription PCR (RT-PCR) from tumor cell lines and normal melanocyte mRNA.
- Sequence comparison between tumor and normal cells to identify mutations.
Main Results:
- A UVR signature point mutation (C --> T transition) was identified in exon 2 of the CDKN2A gene in an opossum corneal tumor cell line.
- This mutation site is known to affect CDKN2A's ability to bind CDK4, potentially leading to uncontrolled cell cycling.
- Amino acid sequence identity of opossum CDKN2A relative to human, mouse, and rat ranged from 57-63% (identity) and 63-67% (similarity).
- Amino acid identity and similarity for p19ARF ranged from 39-49%.
Conclusions:
- The identified UVR signature mutation in the opossum CDKN2A gene supports its role in UVR-induced tumor development.
- Monodelphis domestica serves as a relevant model for studying the genetic mechanisms of melanoma induced by UVR.
- Further research can explore therapeutic strategies targeting the CDKN2A pathway in UVR-associated skin cancers.